Whetting pharma's appetite

Early Bird Dealmaking

Though deals for late stage products promise a more timely impact on earnings, the need for innovation remains urgent for pharma licensing specialists, who say they are willing to pay more for earlier technology because the quality of biotech R&D is increasing...